This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
According to figures published in the DEA’s Domestic Cannabis Eradication/Suppression Statistical Report , the agency and its law enforcement partners confiscated an estimated four million marijuana plants in 2019 – up from 2.8 It was the second-lowest number of arrests reported by the DEA in the past decade.
A federal court has ordered the Drug Enforcement Administration to respond to a lawsuit charging the agency with failing to move forward with a 2016 policy to expand the total number of federally licensed marijuana cultivators. “[This filing is] asking the court for an order compelling the DEA to process our application.
DEA Potential Reclassification of Marijuana Policy. In recent discussions surrounding drug policy reform, the reclassification of marijuana by the Drug Enforcement Administration (DEA) has emerged as a pivotal issue. Read More
As a result, the DEA has been encouraged for over a decade to expand the pool of federally licensed cannabis producers — a move that the agency has largely resisted. In 2016, the agency appeared to reconsider its longstanding policy, and publicly stated for the first time that it would consider additional applicants.
The US Drug Enforcement Administration (DEA) has once again pledged to take action to better facilitate clinical cannabis research. In 2016, the DEA similarly announced the adoption of new rules to expand to supply of research-grade cannabis, but failed to take any further action.
Drug Enforcement Administration (DEA) will move to reclassify cannabis — a historic shift that could have wide ripple effects across the country. Understanding current drug scheduling for cannabis The DEA classifies drugs, substances, and certain chemicals used to make drugs into five distinct categories or “schedules.”
"Although Congress has failed to amend federal cannabis laws to explicitly recognize state-legal cannabis markets, the attitudes and priorities of federal law enforcement agents and prosecutors have clearly shifted in a manner that reflects their reality.
Members of the House Energy and Commerce Subcommittee on Health today held a legislative hearing, “ Cannabis Policies for the New Decade ,” during which they considered multiple legislative bills aimed at amending federal cannabis laws. He continued: “The fact of the matter is that legalization and regulation work.
Its provocative kicker states: Much of whats sold as hemp today isnt hemp at all its a mix of synthetic intoxicants and illicit THC masquerading as a legal, natural product. There’s also THCP, THCO, HHC, and others that can’t be made from CBD starter material and thus are outside the legal definition of “hemp.”
In August 2016, the US Drug Enforcement Administration announced in the US Federal Register that the agency was “adopting a new policy that is designed to increase the number of entities registered under the Controlled Substances Act to grow (manufacture) marijuana to supply legitimate researchers in the United States.”
Moreover, the ball is in the Drug Enforcement Agency’s (DEA) court. The FDA can make recommendations to the DEA about substances subjected to scheduling under the CSA, but the DEA is the entity with the power to reschedule CBD. In the recent case Hemp Industries Associations v.
This Wednesday, January 15th, at 10 am EST, the House Energy and Commerce Subcommittee on Health will hold a legislative hearing entitled “Cannabis Policies for the New Decade.” ” This marks the first time that members of the Energy and Commerce Committee will hear and debate issues specific to marijuana policy reform.
Drug Enforcement Administration (DEA) when it comes to DEA’s handling of petitions to remove marijuana from the list of most dangerous drugs. Since then many different parties have tried to reschedule or end prohibition by filing petitions with DEA per the CSA protocol on rescheduling.
One might think that the recent uptick in the legalization of recreational marijuana usage would correlate with a decline in the arrests and seizures related to the leafy-green. In 2020 alone, legal sales of marijuana in the US bought in a record $17.5 Nevertheless, the federal law and enforcement policy remained the same.
Some states have regulated Hemp CBD despite the FDA’s slow movement, others are locked into the FDA’s policy, banning Hemp CBD in foods and dietary supplements. A positive statement like this from Dr. Hahn, made directly to the NASDA is likely to have ripple effects on enforcement policies across the state. Conclusion.
During a recent interview with the Brookings Institution, Scott Gottlieb, the departing head of the Food and Drug Administration (“FDA”), explained it would take several years for the agency to come up with rules that would legalize the use of hemp-derived cannabidiol (Hemp-CBD) in food products, unless Congress steps in.
states and the District of Columbia currently have legal cannabis, medical or recreational. Despite this massive shift in cannabis policy, however, a few states are still dragging their feet on cannabis legalization. To its credit, the state does seem to be making minor strides toward cannabis legalization lately.
Department of Agriculture (“USDA”) released a statement, in which the agency clarified that the passage of the 2018 Farm Bill rendered the importation of hemp seeds legal. As we previously explained , the 2018 Farm Bill legalized hemp, hemp seeds, and other derivatives by removing them from the Controlled Substance Act.
As we reported earlier , marijuana experts were frustrated over the poor quality of cannabis grown at the government’s only legal marijuana facility at the University of Mississippi. Despite a 90-day deadline for review, the DEA ignored this cut-off and simply sat on the applications for three years. Dozens of Applications”. .
In the preliminary emails and phone calls, a very common question those lawyers ask is this: “The FDA has stated that it is ‘not legal’ to introduce THC or CBD products into the marketplace. The FDA has taken a “not legal” position on hemp-CBD in consumables through its oft-cited FAQ and elsewhere. What are we are missing?”
This occasion marks the first time that a federal agency has recommended rescheduling cannabis, and this could be the push the Drug Enforcement Administration (DEA) needs to finally make it happen. With cannabis’ current status as a Schedule I drug, it’s challenging for the federal government to push for nationwide legalization.
Rather than a ballot initiative , Connecticut, New Mexico, New York, and Virginia legalized the plant for adult-use purposes via a legislative process. They follow in the footsteps of Vermont, which became the first legislative-driven legal cannabis state back in 2018. Legal Cannabis Business Framework .
The recommendation by the FDA and HHS to reclassify marijuana as a Schedule III substance marks a pivotal shift in federal drug policy, acknowledging its medical benefits and potential for lower abuse.
Drug Enforcement Agency (DEA) made far fewer cannabis-related arrests in 2019 than in previous years. Let’s take a closer look at what DEA data reveals. Much of it was caused by the statistics coming out of California, where legalized markets have struggled to match the quality and affordability of more experienced black market rivals.
Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news: CBD. Congressional report offers overview of CBD/hemp market, policy challenges. The report doesn’t weigh in on delta-8-THC, which can be derived from legal hemp but isn’t regulated under federal statute. Published To JD Supra. Marijuana Moment.
Still, for all its promise, would-be clinic owners, practitioners, and consumers may be confused about the legality of such clinics. What are the exact legalities behind ketamine? Failure to follow these very specific legal directives can lead to immediate criminal liability under federal law.
Welcome back to The Week in Weed, your Friday look at what’s happening in the world of legalized marijuana. We’ve talked quite a bit about South Dakota over the years; most recently, we’ve been watching the progress of their hemp legalization legislation. DEA GUIDANCE. LEGALIZATION EFFORTS.
The annual DEA report also shows that federal law enforcement officers made nearly 5,000 cannabis-related arrests in 2020, a year wracked by the social and economic fallout of the Covid-19 pandemic. Nationwide, agents seized more than $41 million in assets related to the DEA’s marijuana eradication efforts in 2020.
Colorado could legalize psychedelics. This campaign was backed by New Approach PAC, a nationwide political organization that is focused on supporting progressive reform surrounding cannabis and criminal justice policies. The city of Denver, Colorado, decriminalized the possession and use of psilocybin in 2019—the first U.S.
The Initiative anticipated a two-part process: first, seeking open records disclosures from the government to understand how it views and handles ayahuasca; and second, pursuing the legal recognition of the CEC as a legitimate ayahuasca church founded in the United States based on indigenous beliefs. Drug Enforcement Agency (“DEA”).
Drug Enforcement Administration (DEA) quietly made an announcement that’s expected to have a profound and long-lasting impact on cannabis research and development in the United States. For years, NIDA and the DEA have promised to open up the sourcing of federally-approved research cannabis. DEA finally relents.
In the 2020 National Drug Threat Assessment , which was released by the DEA on Wednesday, the agency notes that despite its continued illegality under federal law, marijuana “is the most commonly used illicit drug in the United States.”. This has led to the saturation of some markets, particularly in states that have legalized cannabis.
Reuters Reports have surfaced indicating that the Biden administration is gearing up to shake up federal drug policy. Drug Enforcement Administration (DEA) is reportedly considering reclassifying marijuana, a move that could mark a significant shift in decades-long restrictions. According to NBC News, the DEA is set to greenlight.
As the legality of hemp and cannabis products strengthens, people are curious to learn more about the different compounds they contain. percent or less to be legally sold. The Legality of CBD and THC. However, the DEA and FDA still consider CBD a drug regulated under the Schedule I classification. Defining CBD and THC.
We have noted previously that the federal Drug Enforcement Agency (DEA) recently announced that drugs that include CBD (cannabidiol) with less than 0.1% We had previously blogged on The Stoned Age: What the CBD Craze Means for Employers and Their Substance Abuse Policies , CBD is Everywhere – But Where Does the FDA Stand? ,
Well, the DEA just released its 2020 National Drug Threat Assessment, and the report is full of stats on the United States’ most popular illegal addictions, new trends in intoxicants, and foreign trade — a.k.a. The US sourced 92 percent of its heroin from Mexico in 2019, according to product analyzed by a DEA tracing program.
The DEA’s announcement signals the “beginning of the end” of federal marijuana prohibition, as the policy change allows federal agencies to evaluate and assess the medical use and abuse potential of marijuana with (limited) political interference. BY EMILY BURNS, GREEN LIGHT LAW GROUP —.
Medical: Legal Recreational: Ilegal. In 2018, like many other countries to do so that year, the South Korean government passed legislation legalizing the use of medical marijuana, albeit under a strict set of guidelines and regulations. South Korea was the first country in East Asia to legalize cannabis for medical purposes.
One might think that the recent uptick in the legalization of recreational marijuana usage would correlate with a decline in the arrests and seizures related to the leafy-green. In 2020 alone, legal sales of marijuana in the US bought in a record $17.5 Nevertheless, the federal law and enforcement policy remained the same.
One might think that the recent uptick in the legalization of recreational marijuana usage would correlate with a decline in the arrests and seizures related to the leafy-green. In 2020 alone, legal sales of marijuana in the US bought in a record $17.5 Nevertheless, the federal law and enforcement policy remained the same.
MAPS worked for over 22 years to obtain marijuana for medical marijuana drug development research, and the approval is a historic shift in federal policy. The study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs). 5 cannabis strains to treat PTSD: 1. Blue Dream.
As the Drug Enforcement Administration (DEA) and federal government draw closer to moving cannabis from a Schedule I to a Schedule III substance , more groups have begun to put their weight behind the movement. While there is no date yet on when the formal decision from the DEA will be released, it could be as soon as a few weeks from now.
CannaTech showcases the biggest industry thought leaders, known for their significant and groundbreaking contributions to the global cannabis market in fields such as science, finance, government policy and tech. policy towards marijuana. Where is it all headed?” Cannabis evolution under the Obama Administration.
Pennington, who focuses on federal appeals and regulatory issues, is co-counsel on several high-profile cases against the DEA regarding cannabis research, hemp, and psychedelics. Circuit), a pending petition for review of DEA’s August 2020 Interim Final Rule purportedly implementing the 2018 Farm Bill’s amendments to the CSA.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content